Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT05168969 |
Other study ID # |
21CH164 |
Secondary ID |
ANSM |
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
July 2, 2022 |
Est. completion date |
December 10, 2022 |
Study information
Verified date |
April 2023 |
Source |
Centre Hospitalier Universitaire de Saint Etienne |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
A few years ago, a new genetic disorder (OMIM # 615075) has been associated with
loss-of-function variations in the CTNNB1 gene. The clinical features include a delayed
psychomotor development usually leading to severe intellectual disability with or without
autistic spectrum disorders, progressive spastic diplegia, and various visual defects. Among
over 30 cases described worldwide, 2 were reported with an exaggerated startle response to
sudden stimulus corresponding to a very rare neurological phenomenon called hyperekplexia.
The investigators also have a 3rd patient carrying a CTNNB1 syndrome associated with
hyperekplexia.
Description:
Hyperekplexia can impair daily life because the affected person will fall unexpectedly and
stiffly, causing repeated head- or body- wounds. It may be treated empirically by various
drugs. Hyperekplexia has so far not been associated with CTNNB1 variations.
In this study, we aim to describe the prevalence and clinical characteristics of
hyperekplexia in CTNNB1 syndrome carriers, in order to improve diagnosis and thus treatment.
The investigators will recruit CTNNB1 subjects through health care providers and also by
contacting the families through dedicated social media and databases. The families and health
care providers will be invited to fill in a questionnaire related to hyperekplexia (clinical,
pharmacological, and genetic data).